Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

William R. Drobyski MD

William R. Drobyski MD

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center


Publications

  • Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. (Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN) Am J Hematol 2017 Oct;92(10):E610-E611 PMID: 28699171 07/13/2017
  • Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 04/17/2017
  • Loss of free fatty acid receptor 2 enhances colonic adenoma development and reduces the chemopreventive effects of black raspberries in ApcMin/+ mice. (Pan P, W Skaer C, Wang HT, Oshima K, Huang YW, Yu J, Zhang J, M Yearsley M, A Agle K, R Drobyski W, Chen X, Wang LS) Carcinogenesis 2017 Jan;38(1):86-93 PMID: 27866157 PMCID: PMC5219051 11/21/2016
  • Effects of Donor Vitamin A Deficiency and Pharmacologic Modulation of Donor T Cell Retinoic Acid Pathway on the Severity of Experimental Graft-versus-Host Disease. (Dodge J, Stephans A, Lai J, Drobyski WR, Chen X) Biol Blood Marrow Transplant 2016 Dec;22(12):2141-2148 PMID: 27596131 09/07/2016
  • Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. (Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M) Bone Marrow Transplant 2016 Dec;51(12):1602-1604 PMID: 27595288 09/07/2016
  • A colitogenic memory CD4+ T cell population mediates gastrointestinal graft-versus-host disease. (Zhou V, Agle K, Chen X, Beres A, Komorowski R, Belle L, Taylor C, Zhu F, Haribhai D, Williams CB, Verbsky J, Blumenschein W, Sadekova S, Bowman E, Ballantyne C, Weaver C, Serody DA, Vincent B, Serody J, Cua DJ, Drobyski WR) J Clin Invest 2016 Sep 01;126(9):3541-55 PMID: 27500496 PMCID: PMC5004941 08/09/2016
  • Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression. (Belle L, Agle K, Zhou V, Yin-Yuan C, Komorowski R, Eastwood D, Logan B, Sun J, Ghilardi N, Cua D, Williams CB, Gaignage M, Marillier R, van Snick J, Drobyski WR) Blood 2016 Oct 20;128(16):2068-2082 PMID: 27488350 PMCID: PMC5073185 08/05/2016
  • Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. (Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M) Bone Marrow Transplant 2017 Jan;52(1):147-150 PMID: 27479688 08/02/2016
  • Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. (Lazaryan A, Wang T, Spellman SR, Wang HL, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, Page K, Bitan M, Reshef R, Drobyski W, Marsh SG, Schultz K, Müller CR, Fernandez-Viña MA, Verneris MR, Horowitz MM, Arora M, Weisdorf DJ, Lee SJ) Haematologica 2016 Oct;101(10):1267-1274 PMID: 27247320 PMCID: PMC5046657 06/02/2016
  • Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. (Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN) Clin Lymphoma Myeloma Leuk 2016 Jul;16(7):379-86 PMID: 27160644 05/11/2016
  • DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation. (Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ) Case Rep Med 2016;2016:8503275 PMID: 26941799 PMCID: PMC4749780 03/05/2016
  • Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. (Cornell RF, Hari P, Drobyski WR) Biol Blood Marrow Transplant 2015 Dec;21(12):2061-2068 PMID: 26327628 PMCID: PMC4639405 09/04/2015
  • Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. (Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN) Bone Marrow Transplant 2015 Jul;50(7):914-7 PMID: 25915809 04/29/2015
  • Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. (Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M, Palmer J, Pasquini M, Rizzo DJ, Saber W, Hari P, Fenske TS) Bone Marrow Transplant 2015 Jul;50(7):947-53 PMID: 25867651 PMCID: PMC4490016 04/14/2015
  • Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. (Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ, Graft-vs-Host Disease Working Committee of the CIBMTR) Biol Blood Marrow Transplant 2015 Feb;21(2):266-74 PMID: 25445023 PMCID: PMC4326247 12/03/2014
  • Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. (Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2014 Dec;20(12):1926-31 PMID: 25111581 08/12/2014
  • Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. (Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN) Biol Blood Marrow Transplant 2014 Mar;20(3):402-408.e1 PMID: 24342394 PMCID: PMC3961011 12/18/2013
  • Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. (Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, Litzow MR, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ) Leukemia 2014 Mar;28(3):658-65 PMID: 23989431 PMCID: PMC3951192 08/31/2013
  • Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. (Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR) Biol Blood Marrow Transplant 2013 Sep;19(9):1368-73 PMID: 23806770 06/29/2013
  • The role of regulatory T cells in the biology of graft versus host disease. (Beres AJ, Drobyski WR) Front Immunol 2013;4:163 PMID: 23805140 PMCID: PMC3690651 06/28/2013
  • A critical role for the retinoic acid signaling pathway in the pathophysiology of gastrointestinal graft-versus-host disease. (Chen X, Dodge J, Komorowski R, Drobyski WR) Blood 2013 May 09;121(19):3970-80 PMID: 23529927 PMCID: PMC3650708 03/27/2013
  • Salvage second hematopoietic cell transplantation in myeloma. (Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research) Biol Blood Marrow Transplant 2013 May;19(5):760-6 PMID: 23298856 PMCID: PMC3816739 01/10/2013
  • CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. (Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR) J Immunol 2012 Jul 01;189(1):464-74 PMID: 22649199 PMCID: PMC3381996 06/01/2012
  • Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease. (Rangarajan H, Yassai M, Subramanian H, Komorowski R, Whitaker M, Gorski J, Drobyski WR) Blood 2012 Jun 28;119(26):6354-64 PMID: 22496151 PMCID: PMC3383195 04/13/2012
  • HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies. (Battiwalla M, Ellis K, Li P, Pavletic SZ, Akpek G, Hematti P, Klumpp TR, Maziarz RT, Savani BN, Aljurf MD, Cairo MS, Drobyski WR, George B, Hahn T, Khera N, Litzow MR, Loren AW, Saber W, Arora M, Urbano-Ispizua A, Cutler C, Flowers ME, Spellman SR) Biol Blood Marrow Transplant 2012 Aug;18(8):1302-8 PMID: 22414493 PMCID: PMC3580851 03/15/2012
  • Surgical resection as definitive treatment for refractory GVHD of the colon. (Cornell RF, Palmer J, Komorowski R, Drobyski WR) Bone Marrow Transplant 2012 Oct;47(10):1366-7 PMID: 22327134 02/14/2012
  • T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. (Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J) Biol Blood Marrow Transplant 2012 Jun;18(6):937-43 PMID: 22155505 PMCID: PMC3319849 12/14/2011
  • Tocilizumab for the treatment of steroid refractory graft-versus-host disease. (Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, Saber W, Hari P) Biol Blood Marrow Transplant 2011 Dec;17(12):1862-8 PMID: 21745454 PMCID: PMC3716013 07/13/2011
  • Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. (Beres A, Komorowski R, Mihara M, Drobyski WR) Clin Cancer Res 2011 Jun 15;17(12):3969-83 PMID: 21558402 PMCID: PMC3117905 05/12/2011
  • Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. (Hallett WH, Jing W, Drobyski WR, Johnson BD) Biol Blood Marrow Transplant 2011 Aug;17(8):1133-45 PMID: 21536144 05/04/2011
  • Gastrointestinal pathology of autologous graft-versus-host disease following hematopoietic stem cell transplantation: a clinicopathological study of 17 cases. (Cogbill CH, Drobyski WR, Komorowski RA) Mod Pathol 2011 Jan;24(1):117-25 PMID: 20953169 10/19/2010
  • Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses. (Das R, Komorowski R, Hessner MJ, Subramanian H, Huettner CS, Cua D, Drobyski WR) Blood 2010 Jun 24;115(25):5249-58 PMID: 20382845 PMCID: PMC2892952 04/13/2010
  • Robert Truitt tribute. (Johnson B, Drobyski W, Blazar B, Korngold R) Biol Blood Marrow Transplant 2010 Jan;16(1):143-4 PMID: 19836456 10/20/2009
  • Immune reconstitution: how it should work, what's broken, and why it matters. (Gress RE, Emerson SG, Drobyski WR) Biol Blood Marrow Transplant 2010 Jan;16(1 Suppl):S133-7 PMID: 19819340 PMCID: PMC2832716 10/13/2009
  • Interleukin 17 is not required for autoimmune-mediated pathologic damage during chronic graft-versus-host disease. (Chen X, Das R, Komorowski R, van Snick J, Uyttenhove C, Drobyski WR) Biol Blood Marrow Transplant 2010 Jan;16(1):123-8 PMID: 19772944 PMCID: PMC2804961 09/24/2009
  • Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease. (Filicko-O'Hara J, Grosso D, Flomenberg PR, Friedman TM, Brunner J, Drobyski W, Ferber A, Kakhniashvili I, Keever-Taylor C, Mookerjee B, Talano JA, Wagner JI, Korngold R, Flomenberg N) Biol Blood Marrow Transplant 2009 Dec;15(12):1609-19 PMID: 19744572 PMCID: PMC2783272 09/12/2009
  • Posterior reversible encephalopathy syndrome as a consequence of high dose steroid administration after autologous PBSCT. (Sukumaran S, George B, Nair HP, Drobyski WR) Bone Marrow Transplant 2010 Apr;45(4):779-80 PMID: 19684634 08/18/2009
  • Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. (Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, Drobyski WR) Blood 2009 Jul 23;114(4):891-900 PMID: 19491393 PMCID: PMC2716024 06/06/2009
  • Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. (Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR) Blood 2009 Mar 05;113(10):2352-62 PMID: 19059877 PMCID: PMC2652376 12/09/2008
  • Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. (Drobyski WR, Hari P, Keever-Taylor C, Komorowski R, Grossman W) Bone Marrow Transplant 2009 Jan;43(2):169-77 PMID: 18762759 09/03/2008
  • Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. (Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, Drobyski W, Wang D, Pavletic S, Ringden O, Horowitz MM, Collins R Jr) Bone Marrow Transplant 2008 Aug;42(3):201-5 PMID: 18490913 05/21/2008
  • Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. (Cohen EP, Irving AA, Drobyski WR, Klein JP, Passweg J, Talano JA, Juckett MB, Moulder JE) Int J Radiat Oncol Biol Phys 2008 Apr 01;70(5):1546-51 PMID: 18029109 PMCID: PMC2386758 11/22/2007
  • Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. (Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR) Blood 2007 Nov 15;110(10):3804-13 PMID: 17693581 PMCID: PMC2077325 08/19/2007
  • Significant increase in end-stage renal disease after hematopoietic stem cell transplantation. (Cohen EP, Drobyski WR, Moulder JE) Bone Marrow Transplant 2007 May;39(9):571-2 PMID: 17351643 03/14/2007
  • Homeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. (Gorski J, Chen X, Gendelman M, Yassai M, Krueger A, Tivol E, Logan B, Komorowski R, Vodanovic-Jankovic S, Drobyski WR) Blood 2007 Jun 15;109(12):5502-10 PMID: 17347406 PMCID: PMC1890817 03/10/2007
  • Gammadelta T cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection. (Vodanovic-Jankovic S, Drobyski WR) Biol Blood Marrow Transplant 2006 Nov;12(11):1125-34 PMID: 17085305 PMCID: PMC1679815 11/07/2006
  • NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. (Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR) Blood 2006 Jan 15;107(2):827-34 PMID: 16174760 PMCID: PMC1895627 09/22/2005
  • Emergent autoimmunity in graft-versus-host disease. (Tivol E, Komorowski R, Drobyski WR) Blood 2005 Jun 15;105(12):4885-91 PMID: 15746077 PMCID: PMC1894995 03/05/2005
  • Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity? (Hari P, Logan B, Drobyski WR) Biol Blood Marrow Transplant 2004 Nov;10(11):743-7 PMID: 15505605 10/27/2004
  • The role of allogeneic transplantation in high-risk acute myelogenous leukemia. (Drobyski WR) Leukemia 2004 Oct;18(10):1565-8 PMID: 15452588 09/29/2004
  • Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration. (Gendelman M, Halligan N, Komorowski R, Logan B, Murphy WJ, Blazar BR, Pritchard KA Jr, Drobyski WR) Blood 2005 Jan 01;105(1):428-31 PMID: 15331451 08/28/2004
  • Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease. (Gendelman M, Hecht T, Logan B, Vodanovic-Jankovic S, Komorowski R, Drobyski WR) J Immunol 2004 Mar 01;172(5):3328-36 PMID: 14978141 02/24/2004
  • Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. (Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR) Biol Blood Marrow Transplant 2003 Dec;9(12):742-52 PMID: 14677113 12/17/2003
  • Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. (Burt RK, Drobyski WR, Seregina T, Traynor A, Oyama Y, Keever-Taylor C, Stefka J, Kuzel TM, Brush M, Rodriquez J, Burns W, Tennant L, Link C) Exp Hematol 2003 Oct;31(10):903-10 PMID: 14550806 10/11/2003
  • Concurrent presence of both patient and donor t(14;18) in a follicular lymphoma patient after undergoing allogeneic BMT: implications for minimal residual disease detection post-transplant. (Rosenblum MD, Drobyski WR, Keever-Taylor C, Chang CC) Bone Marrow Transplant 2003 May;31(10):947-9 PMID: 12748676 05/16/2003
  • Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation. (Drobyski WR, Gendelman M, Vodanovic-Jankovic S, Gorski J) J Immunol 2003 Mar 15;170(6):3046-53 PMID: 12626559 03/11/2003
  • Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene. (Drobyski WR, Gendelman M) Leuk Lymphoma 2002 Oct;43(10):2011-6 PMID: 12481900 12/17/2002
  • Role of the passive apoptotic pathway in graft-versus-host disease. (Drobyski WR, Komorowski R, Logan B, Gendelman M) J Immunol 2002 Aug 01;169(3):1626-33 PMID: 12133993 07/23/2002
  • Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. (Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 2002 Feb 01;99(3):806-14 PMID: 11806980 01/25/2002
  • Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. (Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Leis J, Holmes HE, Johnson M, Horowitz M, Collins RH Jr) J Clin Oncol 2002 Jan 15;20(2):405-12 PMID: 11786567 01/12/2002
  • Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. (Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR) Biol Blood Marrow Transplant 2001;7(11):620-30 PMID: 11760150 01/05/2002
  • Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. (Drobyski WR, Morse HC 3rd, Burns WH, Casper JT, Sandford G) Blood 2001 Apr 15;97(8):2506-13 PMID: 11290616 04/06/2001
  • Donor leukocyte infusions for multiple myeloma. (Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A, Porter D, Giralt S, Levine JE, Drobyski W, Barrett AJ, Horowitz M, Collins RH) Bone Marrow Transplant 2000 Dec;26(11):1179-84 PMID: 11149728 01/10/2001
  • Quantitative evaluation of post-bone marrow transplant engraftment status using fluorescent-labeled variable number of tandem repeats. (Luhm RA, Bellissimo DB, Uzgiris AJ, Drobyski WR, Hessner MJ) Mol Diagn 2000 Jun;5(2):129-38 PMID: 11066014 11/07/2000
  • Donor leukocyte infusions in acute lymphocytic leukemia. (Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, Barrett J, Johnson M, Kirk A, Horowitz M, Parker P) Bone Marrow Transplant 2000 Sep;26(5):511-6 PMID: 11019840 10/06/2000
  • Adoptively transferred gamma delta T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice. (Drobyski WR, Vodanovic-Jankovic S, Klein J) J Immunol 2000 Aug 01;165(3):1634-40 PMID: 10903774 07/21/2000
  • Evolving strategies to address adverse transplant outcomes associated with T cell depletion. (Drobyski WR) J Hematother Stem Cell Res 2000 Jun;9(3):327-37 PMID: 10894354 07/14/2000
  • T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. (Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringdén O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM) Blood 2000 Jun 15;95(12):3996-4003 PMID: 10845940 06/14/2000
  • Adoptive immunotherapy using donor leukocyte infusions to treat relapsed hematologic malignancies after allogeneic bone marrow transplantation. (Drobyski WR) Cancer Treat Res 1999;101:233-66 PMID: 10800652 05/09/2000
  • Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. (Porter DL, Collins RH Jr, Hardy C, Kernan NA, Drobyski WR, Giralt S, Flowers ME, Casper J, Leahey A, Parker P, Mick R, Bate-Boyle B, King R, Antin JH) Blood 2000 Feb 15;95(4):1214-21 PMID: 10666193 02/09/2000
  • Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes. (Burt RK, Drobyski WR, Traynor AE, Link CJ Jr) Bone Marrow Transplant 1999 Nov;24(10):1043-51 PMID: 10578153 12/01/1999
  • Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease. (Drobyski WR, Majewski D, Hanson G) Biol Blood Marrow Transplant 1999;5(4):222-30 PMID: 10465102 08/28/1999
  • Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. (Porter DL, Collins RH Jr, Shpilberg O, Drobyski WR, Connors JM, Sproles A, Antin JH) Biol Blood Marrow Transplant 1999;5(4):253-61 PMID: 10465105 08/28/1999
  • T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. (Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 1999 Jul 15;94(2):434-41 PMID: 10397710 07/09/1999
  • The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia. (Drobyski WR, Hessner MJ) Leuk Lymphoma 1998 Oct;31(3-4):317-23 PMID: 9869195 12/30/1998
  • Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. (Drobyski WR, Majewski D, Ozker K, Hanson G) J Immunol 1998 Sep 01;161(5):2610-9 PMID: 9725263 09/02/1998
  • Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia. (Drobyski WR, Pelz C, Kabler-Babbitt C, Hessner M, Baxter-Lowe LA, Keever-Taylor CA) Biol Blood Marrow Transplant 1998;4(1):3-12 PMID: 9701386 08/13/1998
  • T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. (Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski WR, Hanson G, Horowitz M, Lawton C, Margolis J, Peitryga D, Vesole D) Bone Marrow Transplant 1998 May;21(9):893-9 PMID: 9613781 06/05/1998
  • Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. (Lawton CA, Cohen EP, Murray KJ, Derus SW, Casper JT, Drobyski WR, Horowitz MM, Moulder JE) Bone Marrow Transplant 1997 Dec;20(12):1069-74 PMID: 9466280 02/18/1998
  • Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HGTRI 0103. (Link CJ Jr, Burt RK, Traynor AE, Drobyski WR, Seregina T, Levy JP, Gordon L, Rosen ST, Burns WH, Camitta B, Casper J, Horowitz M, Juckett M, Lawton C, Margolis D, Pietryga D, Rowlings P, Taylor C, Furtado M, Stefka J, Gupta-Burt S, Kaiser H, Vesole DH) Hum Gene Ther 1998 Jan 01;9(1):115-34 PMID: 9458247 02/11/1998
  • Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia. (Drobyski WR, Endean DJ, Klein JP, Hessner MJ) Br J Haematol 1997 Aug;98(2):458-66 PMID: 9266951 08/01/1997
  • Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. (Kawanishi Y, Passweg J, Drobyski WR, Rowlings P, Cook-Craig A, Casper J, Pietryga D, Garbrecht F, Camitta B, Horowitz M, Juckett M, Margolis D, Flomenberg N, Keever-Taylor CA) Bone Marrow Transplant 1997 Jun;19(11):1069-77 PMID: 9193748 06/01/1997
  • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. (Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J) J Clin Oncol 1997 Feb;15(2):433-44 PMID: 9053463 02/01/1997
  • Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice. (Drobyski WR, Majewski D) Blood 1997 Feb 01;89(3):1100-9 PMID: 9028343 02/01/1997
  • Modulation of in vitro and in vivo T-cell responses by transferrin-gallium and gallium nitrate. (Drobyski WR, Ul-Haq R, Majewski D, Chitambar CR) Blood 1996 Oct 15;88(8):3056-64 PMID: 8874204 10/15/1996
  • Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts. (Drobyski WR, Majewski D) Blood 1996 Jun 15;87(12):5355-69 PMID: 8652851 06/15/1996
  • Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. (Drobyski WR, Potluri J, Sauer D, Gottschall JL) Bone Marrow Transplant 1996 Jun;17(6):1093-9 PMID: 8807120 06/01/1996
  • Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. (Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR) Blood 1995 Nov 15;86(10):3987-96 PMID: 7579370 11/15/1995
  • Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. (Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR, Ash RC, Horowitz MM, Camitta B, Lawton C) Bone Marrow Transplant 1995 Aug;16(2):271-5 PMID: 7581147 08/01/1995
  • Use of solid phase automated sequencing to define HLA disparity between bone marrow donors and recipients. (Baxter-Lowe LA, Keever C, Dinauer D, Daniels T, Johnson K, Camitta B, Drobyski W, Garbrecht F, Horowitz M, Pietryga D) Transplant Proc 1995 Feb;27(1):1377-8 PMID: 7878917 02/01/1995
  • Inhibition of nitric oxide production is associated with enhanced weight loss, decreased survival, and impaired alloengraftment in mice undergoing graft-versus-host disease after bone marrow transplantation. (Drobyski WR, Keever CA, Hanson GA, McAuliffe T, Griffith OW) Blood 1994 Oct 01;84(7):2363-73 PMID: 7522627 10/01/1994
  • Brief report: fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient. (Drobyski WR, Knox KK, Majewski D, Carrigan DR) N Engl J Med 1994 May 12;330(19):1356-60 PMID: 8152447 05/12/1994
  • Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. (Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F) Blood 1994 Apr 01;83(7):1980-7 PMID: 8142664 04/01/1994
  • Increasing incidence of adenovirus disease in bone marrow transplant recipients. (Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmak GV, McAuliffe T, Camitta B, Horowitz MM, Bunin N) J Infect Dis 1994 Apr;169(4):775-81 PMID: 8133091 04/01/1994
  • Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. (Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS) J Clin Oncol 1994 Mar;12(3):475-82 PMID: 7509852 03/01/1994
  • Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia. (Hessner MJ, Roth MS, Drobyski WR, Baxter-Lowe LA) Genet Anal Tech Appl 1994;11(4):90-4 PMID: 7857690 01/01/1994
  • Component processing and intraoperative autotransfusion during bone marrow harvest. (Cook-Craig A, Owen A, Reeder G, Drobyski W, Horowitz M, Brunner J, Flomenberg N, Keever C) Prog Clin Biol Res 1994;389:613-9 PMID: 7700927 01/01/1994
  • Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. (Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM) Blood 1993 Oct 15;82(8):2310-8 PMID: 8400284 10/15/1993
  • Prevalence of human herpesvirus 6 variant A and B infections in bone marrow transplant recipients as determined by polymerase chain reaction and sequence-specific oligonucleotide probe hybridization. (Drobyski WR, Eberle M, Majewski D, Baxter-Lowe LA) J Clin Microbiol 1993 Jun;31(6):1515-20 PMID: 8391023 PMCID: PMC265570 06/01/1993
  • Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. (Johnson BD, Drobyski WR, Truitt RL) Bone Marrow Transplant 1993 Apr;11(4):329-36 PMID: 8485480 04/01/1993
  • Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow-suppressive role for HHV-6 in vivo. (Drobyski WR, Dunne WM, Burd EM, Knox KK, Ash RC, Horowitz MM, Flomenberg N, Carrigan DR) J Infect Dis 1993 Mar;167(3):735-9 PMID: 8382723 03/01/1993
  • Detection of residual leukemia by the polymerase chain reaction and sequence-specific oligonucleotide probe hybridization after allogeneic bone marrow transplantation for AKR leukemia: a murine model for minimal residual disease. (Drobyski WR, Baxter-Lowe LA, Truitt RL) Blood 1993 Jan 15;81(2):551-9 PMID: 8422472 01/15/1993
  • Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. (Drobyski WR, Roth MS, Thibodeau SN, Gottschall JL) Bone Marrow Transplant 1992 Sep;10(3):301-4 PMID: 1422483 09/01/1992
  • Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4. (Drobyski WR, LeFever AV, Truitt RL) Exp Hematol 1991 Oct;19(9):950-7 PMID: 1716592 10/01/1991
  • Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation. (Carrigan DR, Drobyski WR, Russler SK, Tapper MA, Knox KK, Ash RC) Lancet 1991 Jul 20;338(8760):147-9 PMID: 1677066 07/20/1991
  • Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. (Drobyski WR, Knox KK, Carrigan DR, Ash RC) Transplantation 1991 Jul;52(1):155-7 PMID: 1650043 07/01/1991
  • Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. (Drobyski WR, Gottlieb M, Carrigan D, Ostberg L, Grebenau M, Schran H, Magid P, Ehrlich P, Nadler PI, Ash RC) Transplantation 1991 Jun;51(6):1190-6 PMID: 1646504 06/01/1991
  • Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. (Knox KK, Drobyski WR, Carrigan DR) Lancet 1991 May 25;337(8752):1292-3 PMID: 1674092 05/25/1991
  • Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow. (Drobyski WR, Piaskowski V, Ash RC, Casper JT, Truitt RL) Transplantation 1990 Oct;50(4):625-32 PMID: 1699309 10/01/1990
  • Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. (Drobyski W, Thibodeau S, Truitt RL, Baxter-Lowe LA, Gorski J, Jenkins R, Gottschall J, Ash RC) Blood 1989 Nov 01;74(6):2285-94 PMID: 2572285 11/01/1989
  • Spontaneous regression in non-Hodgkin's lymphoma: clinical and pathogenetic considerations. (Drobyski WR, Qazi R) Am J Hematol 1989 Jun;31(2):138-41 PMID: 2660545 06/01/1989
  • Estrogen receptors and the pattern of relapse in breast cancer. (Qazi R, Chuang JL, Drobyski W) Arch Intern Med 1984 Dec;144(12):2365-7 PMID: 6508445 12/01/1984
  • Last update: 08/17/2017
    jenkins-FCD Prod-132 e0edc266de37dd13c3a3aec79eb87f3c7abc6fa4